3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Hepatocellular
26
Colorectal Neoplasms
9
Neoplasms
7
Carcinoma, Renal Cell
7
Pancreatic Neoplasms
5
Neoplasm Metastasis
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Melanoma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Medullary
2
Wilms Tumor
1
Thrombocytosis
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
cabozantinib
×
Gastrointestinal
×
Clear all
NCT04893785
2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2
Recruiting
35 enrolled